A Study to Investigate the Safety and Efficacy of KQB168 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
Public ClinicalTrials.gov record NCT06994806. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1, Open-label, Multicenter, Dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of KQB168 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Malignancies
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The goal of this clinical trial is to learn if KQB168 works to treat advanced solid tumor cancer in adults. It will also learn about the safety of KQB168. The main questions it aims to answer are: * What is the safe dose of KQB168 by itself or in combination with pembrolizumab? * Does KQB168 alone or in combination with pembrolizumab decrease the size of the tumor? * What happens to KQB168 in the body? Participants will: * Take KQB168 daily, alone or in combination with pembrolizumab * Visit the clinic about 8 times in the first 8 weeks, and then once every 3 weeks after that
Study identification
- NCT ID
- NCT06994806
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 84 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 24, 2025 (Actual)
- Primary completion
- Nov 30, 2027 (Estimated)
- Completion
- May 31, 2028 (Estimated)
- Last update posted
- Mar 3, 2026
2025 – 2028
United States locations
- U.S. sites
- 15
- U.S. states
- 10
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic - Phoenix | Phoenix | Arizona | 85054 | Recruiting |
| USC Norris Comprehensive Cancer Center | Los Angeles | California | 90033 | Recruiting |
| Sarah Cannon Cancer Institute at HealthONE | Denver | Colorado | 80218 | Recruiting |
| Yale Cancer Center- New Haven | New Haven | Connecticut | 06520 | Recruiting |
| Mayo Clinic - Jacksonville | Jacksonville | Florida | 32224 | Recruiting |
| Florida Cancer Specialists - Sarasota | Sarasota | Florida | 34232 | Recruiting |
| University of Iowa | Iowa City | Iowa | 52242 | Recruiting |
| Mayo Clinic - Rochester | Rochester | Minnesota | 55905 | Recruiting |
| Cleveland Clinic | Cleveland | Ohio | 44195 | Recruiting |
| NEXT Austin | Austin | Texas | 78758 | Recruiting |
| Mary Crowley Cancer Research Centers | Dallas | Texas | 75230 | Recruiting |
| UT MD Anderson Cancer Center - Houston | Houston | Texas | 77030 | Recruiting |
| NEXT Huston | Houston | Texas | 77054 | Recruiting |
| NEXT Oncology | San Antonio | Texas | 78229 | Recruiting |
| NEXT Virginia | Fairfax | Virginia | 22031 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06994806, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 3, 2026 · Synced Oct 9, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06994806 live on ClinicalTrials.gov.